# Plain Language Summary: Advancing Education on Biosimilars Act of 2021

This bill is about making sure doctors, patients, and pharmacists understand what biosimilars are and how they work. Biosimilars are medications that are very similar to expensive biologic drugs (drugs made from living cells) but cost significantly less. Think of them like generic versions of these specialty drugs, though they're not exactly the same as traditional generics. The bill directs the federal government to create educational materials and programs to help healthcare providers and patients learn about biosimilars, including how safe and effective they are compared to the original drugs.

The main goal is to increase awareness and understanding of biosimilars so that more people can benefit from these lower-cost treatment options. Right now, many patients and doctors don't know much about biosimilars or may be hesitant to use them because they're less familiar than the original medications. By improving education, the bill aims to help more patients access these drugs at more affordable prices, which could reduce healthcare costs for individuals and the healthcare system overall. This particularly matters for people with chronic conditions like rheumatoid arthritis, Crohn's disease, or certain cancers who rely on expensive biologic medications.

The bill essentially asks federal health agencies to do the educational legwork—creating fact sheets, training programs, and other resources that explain what biosimilars are, how they're approved and regulated, and why they're a safe and cost-effective option. This could help break down barriers that currently prevent biosimilars from being used more widely, ultimately putting more affordable treatment options in the hands of patients who need them.

Advancing Education on Biosimilars Act of 2021

Hassan, Margaret Wood

Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.